Atossa Therapeutics secures up to $16.5M from institutional investors via a registered direct offering of shares and warrants.
Atossa Therapeutics (ATOS) announced a registered direct offering to institutional investors, selling 1.36 million shares or common stock equivalents. The deal includes warrants for up to 2.73 million additional shares, potentially raising $16.5 million in gross proceeds.
The offering follows recent market activity for ATOS, which has seen volatility amid clinical and financial developments. No prior consensus estimate was publicly disclosed for this transaction.
Details on immediate market reaction were not provided in the release.